EUCTR2005-005139-84-CZ进行中（未招募）不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients aged between 18 and 75 years
- •- Histologically or cytologically (fine needle aspiration) proven non-small cell lung cancer (NSCLC)
- •- Untreated locally advanced inoperable stage IIIA (only pN2 confirmed by mediastinoscopy)
- •- Patients with a Karnofsky Performance Status ³ 80%
- •- Adequate pulmonary function
- •- Life expectancy > 12 weeks
- •- Patients without weight loss > 10% within the previous 3 months
- •- Adequate bone marrow, hepatic and renal functions (Neutrophils ³ 2.0 x 109/L-Platelets ³ 100 x 109/L, Haemoglobin ³ 12 g/dL, Total bilirubin £ 1.5 x ULN, Transaminases £ 2.5 x ULN, Alkaline phosphatase < 5 x ULN, Glomerular Filtration Rate ³ 65 mL/min per 1.73 m2·
- •- Presence of at least one measurable lesion (RECIST)
- •- Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol
- •- Absence of current or recent (within 2 weeks before registration) severe infection
- •- Absence of renal or hearing impairment
- •- Women of childbearing potential must be using a medically accepted method of contraception (i.e. oral contraceptives, intrauterine devices) to avoid pregnancy during the 2 months preceding the start of study treatment, throughout the study period and for up to 3 months after the last dose of study treatment in such a manner that the risk of pregnancy is minimised. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study treatment
- •- Fertile men must be using an effective method of birth control if their partners are women of childbearing potential
- •- Patients who give written (personally signed and dated) inform consent before completing any study-related procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with NSCLC stages I, II, bulky IIIA (except pN2 confirmed by mediastinoscopy), IIIB and IV
- •- With tumour extent or location precluding radical radiotherapy as specified in the protocol
- •-Symptomatic neuropathy (sensory) > grade 1 according to the NCI Common Toxicity Criteria
- •- Hearing impairment ³ Grade 2
- •- Concomitant/uncontrolled medical disorder (cardiac failure or myocardial infarction within the previous 3 months; uncontrolled hypertension or arrhythmia; uncontrolled hypercalcaemia; active infection requiring I.V. antibiotics within 2 weeks before the beginning of treatment)
- •- Weight loss > 10% within the previous 3 months
- •- Pre-existing malignant pleural effusion
- •- Ascites or pericardial effusion
- •- Active secondary malignancy except appropriately treated carcinoma in situ of the cervix or skin basal cell cancer. Patients with a history of cancer and at least five years of uneventful follow up and no signs of recurrence may be eligible.
- •- Previous or concomitant treatment with other anticancer drugs during the last 5 years
- •- Known hypersensitivity to the study drugs or to drugs with similar chemical structures
- •- Concomitant treatment with systemic corticosteroids except chronic treatment lasting more than 1 month at low doses (£ 20 mg/day of methyl prednisolone or equivalent)
- •- Significant malabsorption syndrome or disease affecting the gastrointestinal tract function and the absorption of oral drugs
- •- Women if pregnant or breast-feeding or with Positive pregnancy test at inclusion
- •- Male or female of childbearing potential who is unwilling or unable to use a medically accepted method to avoid pregnancy during the 2 months preceding the start of study treatment, throughout the study period and at least 3 months following the last dose of study treatment
- •- Participation to another clinical trial with any investigational drug study (whatever the use, curative, prophylactic or diagnostic intent) within 30 days prior to registration.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CR-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialEUCTR2005-005139-84-ATPIERRE FABRE MEDICAMENT200
进行中（未招募）
1 期
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancerMedDRA version: 8.1Level: LLTClassification code 10025044Term: Lung cancerEUCTR2005-005139-84-FIPIERRE FABRE MEDICAMENT200
进行中（未招募）
1 期
Evaluation of the rate of pathological complete response for neoadjuvant chemoradiotherapy and for chemotherapy alone in locally advanced lung cancer.ocally advanced non small cell lung cancerEUCTR2005-005139-84-ESPIERRE FABRE MEDICAMENT200
招募中
3 期
The effect of chemotherapy in rectal cancerRectal cancer.Malignant neoplasm of rectumIRCT20200803048281N1Tehran University of Medical Sciences70
进行中（未招募）
1 期
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissionGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-HUALTANA Pharma AG